Adiponectin Gene Polymorphisms and Possible Susceptibility to Metabolic Syndrome among the Sudanese Population: A Case-Control Study
Table 3
Comparison of the genotypes and allele frequencies of the ADIPOQ gene polymorphisms (rs266729, rs2241766, and rs1501299) in MetS patients and non-MetS control.
Gene polymorphisms
Group
value
OR
CI lower-upper
MetS
Non-MetS
ADIPOQ rs266729
Genotypes
CC
149 (71.0%)
175 (83.3%)
Reference
CG
48 (22.8%)
32 (15.2%)
1.762
(1.070–2.899)
GG
13 (6.2%)
3 (1.5%)
5.089
(1.423–18.20)
Alleles
C
346 (82.4%)
382 (91.0%)
Reference
G
74 (17.6%)
38 (9.0%)
2.150
(1.416–3.264)
ADIPOQ rs2241766
Genotypes
TT
142 (67.6%)
174 (82.8%)
Reference
TG
58 (27.6%)
34 (16.2%)
2.090
(1.296–3.371)
GG
10 (4.8%)
2 (1.0%)
6.127
(1.321-28.42)
Alleles
T
342 (81.4%)
382 (91.0%)
Reference
G
78 (18.6%)
38 (9.0%)
2.293
(1.515–3.470)
ADIPOQ rs1501299
Genotypes
GG
76 (36.2%)
121 (57.6%)
Reference
GT
101 (48.1%)
82 (39.0%)
1.961
(1.303–2.952)
TT
33 (15.7%)
7 (3.4%)
7.506
(3.161–17.82)
Alleles
G
253 (60.2%)
324 (77.1%)
Reference
T
167 (39.8%)
96 (22.9%)
2.228
(1.650–3.008)
Data are reported as numbers and percentages (%) for genotype counting across all participants (the metabolic syndrome group and control group). Analyses were conducted using the equation of allelic frequencies. A chi-squared test was performed. A two-tailed value ≤0.05 is considered significant. OR: odd ratio, CI: confidence interval.
